Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Vitro Diagnostics, Inc. (OTC: VODG).

Full DD Report for VODG

You must become a subscriber to view this report.


Recent News from (OTC: VODG)

Vitro Biopharma Receives ISO 9001 Certification
GOLDEN, CO / ACCESSWIRE / December 11, 2018 / VitroDiagnostics, Inc. (OTCPK: VODG), dba Vitro Biopharma (''Vitro'') one of theworld's emerging biotechnology companies focused on Umbilical Cord MesenchymalStem Cell (''MSC") research and clinical products has been awarded Certificationto the In...
Source: ACCESSWIRE
Date: December, 11 2018 18:10
Vitro BioPharma Engages Senior Director of Sales and Marketing
GOLDEN, CO / ACCESSWIRE / October 23, 2018 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma, today announced the engagement of a senior Sales and Marketing Director. The company has engaged Keith V. Burge to be its full time Director of Sale and Marketing. Mr. Burge has a B.S....
Source: ACCESSWIRE
Date: October, 23 2018 13:40
Vitro Biopharma 3rd Quarter 2018 Financial Results of Operations and Shareholder Letter
GOLDEN, CO / ACCESSWIRE / September 24, 2018 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma , announced its 3rd quarter financial results of operations, ended July 31 st , 2018. Vitro Diagnostics Inc. ("Vitro") ("VODG") is pleased to announce a record 3rd quarter in Stem Ce...
Source: ACCESSWIRE
Date: September, 24 2018 16:50
Vitro Bio-Pharma 2nd Quarter Ended April 30th 2018 Financial Results of Operations
GOLDEN, CO / ACCESSWIRE / June 26, 2018 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro BioPharma, announced its 2 nd quarter ended April 30 th 2018 financial results of operations. Vitro Diagnostics Inc. (''Vitro'') is pleased to announce a record 2 nd quarter in Stem Cell Revenues....
Source: ACCESSWIRE
Date: June, 26 2018 11:00
Vitro Bio-Pharma Debt Re-Capitalization and Executive Team Formation
GOLDEN, CO / ACCESSWIRE / May 3, 2018 / Vitro Diagnostics, Inc. (OTCQB: VODG), dba Vitro BioPharma, announced today the details of its balance sheet re-capitalization and the formation of its executive team effective April 30 th 2018. The company reorganized $1,003,119 of the company's fou...
Source: ACCESSWIRE
Date: May, 03 2018 09:30
Vitro Bio-Pharma 1st Quarter 2018 Financial Results of Operations
GOLDEN, CO / ACCESSWIRE / March 23, 2018 / Vitro Diagnostics, Inc. (OTC PINK: VODG), dba Vitro BioPharma, announced its 1st quarter ended January 31st, 2018 financial results of operations. Vitro Diagnostics Inc. ("Vitro") is pleased to announce a record 1st quarter in Stem Cell Revenues....
Source: ACCESSWIRE
Date: March, 23 2018 09:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-140.220.220.220.22900
2018-12-130.296950.2390.296950.2394,286
2018-12-120.2525950.250.255080.2526,227
2018-12-110.25010.25010.25010.25015,000
2018-12-100.2550.242050.2550.2420512,772

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-132,1604,28650.3966Short
2018-12-1213,73626,22752.3735Short
2018-12-0413,00018,10071.8232Short
2018-12-033,0008,00037.5000Short
2018-11-123,0003,000100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VODG.


About Vitro Diagnostics, Inc. (OTC: VODG)

Logo for Vitro Diagnostics, Inc. (OTC: VODG)

Develops and manufactures stem cell products for use in research and drug development. Products include adult human stem cells and their fluorescent labeled derivatives, cell culture media for growth and differentiation of stem cells and assay testing systems to determine the quality, potency and response of stem cells to toxic agents.

 

Contact Information

 

 

Current Management

  • James R. Musick / President, CEO

Current Share Structure

  • Market Cap: $1,126,411 - 05/11/2018
  • Authorized: 50,000,000 - 08/30/2010
  • Issue and Outstanding: 19,971,822 - 02/12/2015

 


Recent Filings from (OTC: VODG)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 27 2017
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: October, 13 2017

 

 


Daily Technical Chart for (OTC: VODG)

Daily Technical Chart for (OTC: VODG)


Stay tuned for daily updates and more on (OTC: VODG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: VODG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VODG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VODG and does not buy, sell, or trade any shares of VODG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/